Actinic keratosis (AK) — also known as solar keratosis or sun spots — is a rough, scaly pre-cancer of the epidermis caused by long-term sun exposure. Each lesion has a low individual risk of progression to invasive SCC, but cumulative field risk is meaningful. Treatment options include laser-assisted PDT, topical 5-FU (Efudix), imiquimod (Aldara) and cryotherapy.
- AK is a sun-damage pre-cancer of the epidermis.
- Each individual AK has a low chance of progressing to invasive SCC, but cumulative field risk is meaningful.
- Treatment options include laser-assisted photodynamic therapy (LA-PDT), 5-FU (Efudix), imiquimod (Aldara) and cryotherapy.
- Field therapy treats both visible AKs and the surrounding sub-clinical sun damage.
- Features suggesting progression to SCC — rapid growth, thickening, tenderness, bleeding, treatment failure — should prompt biopsy.
- Daily SPF 50+ and broad sun protection are the most important long-term measures.
Actinic Keratosis(Solar Keratosis)
Actinic keratosis (AK) — also called solar keratosis or a "sun spot" or "age spot" — is a rough, scaly patch on the skin caused by long-term sun exposure. I dislike people colloquially referring to them as "sun spots" or "age spots", because this is better reserved for the harmless sun-damage spot called a solar lentigo. In contrast, AKs are considered a pre-cancer of the epidermis (the top layer of skin). Each individual AK has a low chance of becoming an invasive squamous cell carcinoma (SCC), but patients usually have many AKs in a sun-damaged area ("field"), and the cumulative risk of one of them progressing is meaningful. Treating AKs early prevents progression and clears the field of sun-damaged cells.

By Dr Christopher Irwin, MBChB, FRACGP, MMed (Skin Cancer), FACAM, MSCCA
Published 2026-06-06 · Updated 2026-06-18 · Editorial policy
This page is a hub. Use it to understand what AK is, then go deeper into:
- what AK looks like and why it forms, and
- the best treatment pathways to reduce your future risk.
Quick links
- Targeted skin spot check (1–3 spots)
- Full skin check
- Actinic keratosis treatment options
- Squamous cell carcinoma (SCC)
- How to reduce your chance of getting skin cancer again
- Skin cancer types
The 30-second overview
What is an actinic keratosis?
A sun-damaged patch where the skin cells have become abnormal. It often feels like sandpaper and can look pink, red, skin-coloured or brown.
Is it skin cancer?
AK is a pre-cancer. Many AKs stay stable or come and go, but a proportion can progress to SCC, especially if they become thicker or tender.
Why do doctors talk about “field damage”?
If you have multiple AKs, the skin around them has usually had years of UV exposure — so we often treat the whole zone (not just one spot) to reduce the overall burden and future risk.
When should I get an AK checked urgently?
Book an assessment sooner if an AK is:
- becoming thicker, more raised or lump-like
- tender, painful or persistently itchy
- bleeding, crusting repeatedly or ulcerating
- growing quickly
- on a high-risk site (lip, ear, scalp in a bald area)
These features can suggest progression towards SCC or another diagnosis that needs treatment.
Book a targeted spot check (1–3 spots)
How actinic keratosis develops
What’s happening in your skin
The outer layer of your skin — the epidermis — is built mostly from cells called keratinocytes. Ultraviolet (UV) light, whether from Australia’s intense sun or from solariums, carries enough energy to damage the DNA inside these cells. The occasional sunburn is usually repaired, but decades of cumulative UV exposure eventually outpace that repair, and some keratinocytes begin to grow and mature abnormally. An actinic keratosis is simply what that patch of abnormal cells looks like once it reaches the surface.
Because those cells are still confined to the surface layer, an AK is described as a pre-cancer — it sits at the earliest point on the same pathway that can lead to an invasive squamous cell carcinoma (SCC). Treating an AK early is, in effect, stepping in before that pathway has a chance to progress.
Why the visible spots are only part of the picture
By the time one rough patch is obvious, the surrounding sun-exposed skin has usually built up similar damage that you can’t yet see or feel. Doctors call this field cancerisation, or simply “field change.” Looking through a dermatoscope, we can often pick up far more abnormal skin than is visible to the naked eye.
This is the most important idea on this page. On its own, any single AK carries only a small risk. But a field of sun-damaged skin tends to keep producing new lesions — and the more AKs you accumulate, the greater the overall chance that one of them eventually progresses to SCC. That is why a heavy AK burden is managed as an ongoing plan rather than a one-off freeze, and it is the reason “field treatment” exists.
How we approach AK at The Skin Doctor
AK management isn’t just “freeze the spot.” The best strategy depends on whether you have:
- a single AK (often suitable for targeted treatment), or
- multiple AKs / widespread sun damage (often best managed with a “field treatment” plan).
Field or spot treatment?
The easiest way I’ve found to explain AK treatment to my patients is this.
Imagine a pristine field of brown dirt. You scatter weed seed across it — and that scattering is the equivalent of decades of sun exposure, the UV radiation gradually causing DNA damage to your skin cells.
Come back six to eight weeks later and you’ll see the large weeds from the side of the road. Those are the AKs visible to the naked eye — the pink, brown and rough precancerous patches.
But kneel down in the dirt and it’s a different story: there are countless tiny weeds and seedlings coming up everywhere. That’s what your doctor sees through the dermatoscope — the sub-clinical sun damage spread right across the field.
So if you want to deal with the weeds (the precancer), you have two choices:
- Pull out the biggest weeds — treat only the worst visible lesions. That’s spot treatment (for example, freezing an individual AK).
- Spray the whole field with weedkiller (RoundUp) — treat the entire area in one go. That’s field treatment, using laser-assisted photodynamic therapy or a cream like Efudix.
If you’re the patient who keeps getting “sunspots” every few months, it’s usually a sign you need a longer-term plan — not just repeated one-off treatments.
Learn about AK treatment pathways
When should we treat actinic keratosis?
Actinic keratoses, often called “sun spots” or “solar keratoses”, are areas of sun-damaged skin where some of the surface skin cells have become abnormal. They are considered precancerous because a small proportion can develop into squamous cell carcinoma, or SCC, over time. SCC is usually very treatable when found early, but it is still a true skin cancer and should not be ignored. (4,5,6)
The decision to treat an actinic keratosis depends on the balance between:
- the risk of that lesion progressing;
- the number of lesions and the amount of surrounding sun damage;
- whether the spot is changing, tender, thick, bleeding, ulcerated, or not healing;
- the patient’s overall risk, including previous skin cancers or immune suppression;
- the discomfort, downtime, cost, and temporary cosmetic effects of treatment.
Many people understandably think: “If this is precancerous, shouldn’t we treat it immediately?” Sometimes the answer is yes. But for very mild, flat, asymptomatic actinic keratoses, the decision is more nuanced.
One reason is that treating an actinic keratosis does not reset the skin back to brand-new, undamaged skin. Treatment removes or destroys the most abnormal cells, and the skin then heals from surviving normal-looking keratinocytes in the surrounding epidermis and from deeper skin appendages such as hair follicles. However, in chronically sun-exposed skin, many of these remaining normal-looking cells have also accumulated ultraviolet-related DNA damage. In other words, treatment can clear the visible precancer, but it does not erase decades of sun damage from the whole field of skin. (7,8)
This is why actinic keratoses often recur, or new ones appear, in the same general area over the following years, especially if ongoing UV exposure continues. Treating mild actinic keratoses at the very earliest stage may therefore mean repeatedly treating large field areas — such as the face, scalp, ears, forearms, or backs of the hands — every few years. These treatments can be very worthwhile, but they can also involve redness, crusting, pain, time off work or social activities, cost, and small risks such as infection, pigment change, or scarring. (1,9)
The other key point is that the risk of any one mild actinic keratosis turning into SCC within the next year or two is usually low. Published estimates vary because studies use different patient groups and definitions, but classic and systematic-review data suggest that the annual risk for an individual lesion is often well below 1 in 1,000 per year. In higher-risk populations, such as older patients with many actinic keratoses and previous skin cancers, the risk is higher; one Veterans Affairs study estimated about 0.6% at 1 year and 2.6% at 4 years for progression from a mapped actinic keratosis to SCC or SCC in situ. (4,5,6)
For these reasons, my usual approach is to actively treat actinic keratoses that are moderate, thickened, tender, growing, bleeding, ulcerated, persistent despite treatment, cosmetically troublesome, or occurring in a high-risk patient. For very mild, flat, asymptomatic actinic keratoses, observation and prevention can be reasonable, provided the patient understands the risks and returns for review if the lesion changes.
Prevention is still treatment of the underlying problem. The most important step is reducing ongoing UV exposure: daily broad-spectrum sunscreen, hats, protective clothing, shade, and avoiding unnecessary peak-UV exposure. In selected higher-risk patients, oral nicotinamide, a form of vitamin B3, can also be considered; it has evidence for reducing new actinic keratoses and non-melanoma skin cancers in high-risk immunocompetent patients, although it is not a substitute for sun protection or skin checks. (10,11)
Ultimately, the decision is individual. Some patients prefer to treat even mild lesions early. Others prefer to monitor mild change and reserve treatment for lesions that become thicker or more suspicious. Both approaches can be reasonable when the patient understands the trade-off between a low short-term risk of progression and the discomfort, downtime, and cost of treatment.
Explore actinic keratosis in detail
Actinic keratosis: explanation (what it is, what it looks like, what it means). If you’re trying to work out whether your spot is an AK and what it implies about your skin cancer risk, you’re in the right place.
Actinic keratosis treatment (reducing the burden of sun damage). If you already know you have AKs and want to understand treatment choices — including when “field therapy” is the smarter approach — see actinic keratosis treatment.
Not sure what to book?
- 1–3 specific spots you’re worried about — book a targeted spot check
- Many sunspots, lots of sun damage, or a history of skin cancer — book a full skin check
Symptoms
- Rough, scaly patch on sun-exposed skin
- Sandpaper-like texture
- Pink, red, skin-coloured or brown in colour
- Thickening or becoming raised and lump-like
- Tender, painful or persistently itchy
- Bleeding, repeated crusting or ulceration
- Commonly on the face, scalp, ears, forearms and hands
Causes & contributors
- Cumulative ultraviolet (UV) exposure from sunlight and solariums — the main cause
- Fair skin, light eyes, easy burning
- Older age (but seen in younger Australians with heavy sun exposure)
- Outdoor occupations or hobbies
- Immunosuppression (organ transplant recipients are at much higher risk)
- Past skin cancers or other AKs
Diagnosis
Diagnosis is usually made on clinical examination and dermatoscopy. Biopsy is performed if there is uncertainty about whether a lesion has progressed to invasive SCC, or if a patch fails to respond to treatment. A field of multiple AKs may be graded clinically by Olsen grade (I — easier felt than seen; II — easily seen and felt; III — thicker, hyperkeratotic).
Treatment options
Field therapy — laser-assisted PDT →
For sun-damaged fields with multiple AKs, laser-assisted photodynamic therapy treats the whole area at once. A fractionated laser creates wells in the skin to encourage cream uptake, a sensitising cream is then applied and absorbed into atypical cells, and an LED light activates the cream to destroy them.
Topical creams (5-fluorouracil / Efudix) →
Prescription cream applied to the affected area for around 2–4 weeks. Causes inflammation as abnormal cells die off. Effective for clearing AKs across a field.
Topical imiquimod (Aldara) →
Prescription immunomodulator cream applied over several weeks. Stimulates the immune system to attack abnormal cells. Used for selected sun-damaged fields.
Cryotherapy (liquid nitrogen)
Quick in-clinic spot treatment for individual thicker AKs. Causes a blister that heals over 1-2 weeks. Useful for a small number of obvious lesions but does not treat the surrounding field.
Sun protection
Broad-spectrum SPF 50+ daily, reapplied every 2 hours when outdoors, plus hats and protective clothing. Sun protection is the most effective long-term measure to reduce new AKs and skin cancers.
When to see a doctor
See a doctor if you have rough scaly patches that persist on sun-exposed skin, especially if they are tender, growing, thickening or starting to bleed — features that may suggest progression to invasive SCC. Patients with multiple AKs need ongoing skin surveillance and field therapy.
Frequently asked questions
-
Are actinic keratoses the same as sunspots (freckles)?
No. Freckles and sunspots (lentigines) are pigment changes. AK is a texture change — often rough or scaly — caused by abnormal skin cell growth from UV damage.
-
Can an AK turn into skin cancer?
Some can progress into squamous cell carcinoma (SCC). That’s why persistent, thick, tender or changing AKs should be assessed and treated.
-
Why do AKs keep coming back?
Because AKs often reflect field damage — the surrounding sun-exposed skin has ongoing abnormal change. Treating the whole zone (field therapy) can reduce recurrence better than repeated spot treatments alone.
-
Can I treat AK with over-the-counter creams?
Moisturisers can soften scale, but they don't reliably clear AK. Effective treatments are usually in-clinic procedures (cryotherapy, laser-assisted PDT) or prescription-based field therapies (Efudix, Aldara) — covered in actinic keratosis treatment options.
-
Should I worry if I have lots of AKs?
It’s a sign you need a structured plan and ongoing surveillance. The goal is to reduce AK burden and detect any SCC early.
References
- Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021. (American Academy of Dermatology.)DOI: 10.1016/j.jaad.2021.02.082
- Actinic keratosis — current challenges and unanswered questions. J Eur Acad Dermatol Venereol. 2024.DOI: 10.1111/jdv.19559
- Pre- and post-treatment care for actinic keratoses — an Australian and New Zealand perspective. Aust J Gen Pract. 2025.DOI: 10.31128/AJGP-09-24-7415
- Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988.
- The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013.
- Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009.
- High burden and pervasive positive selection of somatic mutations in normal human skin. Science. 2015.
- Stem cells in the hair follicle bulge contribute to wound repair but not to homeostasis of the epidermis. Nat Med. 2005.
- Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019.
- Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993.
- A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015.
Related
Related conditions
Medically reviewed by Dr Christopher Irwin, MBChB, FRACGP, MMed (Skin Cancer), FACAM, MSCCA · Published 2026-06-06 · Updated 2026-06-18 · Editorial policy